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Background: Recent randomized controlled trials (RCTs) have called into question
whether percutaneous coronary intervention (PCI) reduces death or myocardial
infarction in patients with stable ischemic heart disease (SIHD). However, several of
these trials randomized an unselected group of patients, including those with and
without objective ischemia.
Methods: We performed a meta-analysis of RCTs comparing PCI with medical
therapy (MT) in pts with either ischemia (identiﬁed on non-invasive testing) or
abnormal fractional ﬂow reserve (FFR), to determine whether PCI reduces all-cause
mortality in this high-risk SIHD cohort.
Results: Four RCTs comparing PCI vs. MT in pts with objective ischemia (or FFR-
equivalent) were found; these trials randomized a total of 1,769 pts with f/u from 7
months to 10 years. The point estimate of the hazard ratio (HR) for mortality following
PCI vs. MT varied from 0.33-0.73, with no trial heterogeneity (I2¼0%). Of note, the
documented ischemia cohort of the COURAGE trial (Am Heart J 2012) comprised
48% of the weight of the included studies. Overall, 28/871 (3.2%) PCI pts died
compared with 54/898 MT pts (6.0%), consistent with a signiﬁcant reduction in all-
cause mortality with PCI (HR 0.56; 95% conﬁdence interval (CI): 0.34-0.93, p¼0.02,
Figure), which remained signiﬁcant when 3 other ineligible RCTs were added which
included a PCI vs MT arm (HR 0.61 [0.42,0.89], p¼0.01).JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Despite conventional conclusions drawn from existing RCT data that
PCI and MT result in comparable survival in SIHD, when analyses are restricted to pts
with objective ischemia (or the FFR equivalent), PCI is associated with a signiﬁcant
and consistent 44% reduction in all-cause mortality compared with MT.
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Background: Studies indicate no clear beneﬁt of early percutaneous coronary inter-
vention (PCI) (<24 hours) in non ST elevation acute coronary syndrome (NSTE-
ACS) patients as compared to delayed PCI (>24 hours). However, high risk NSTE-
ACS patients may beneﬁt from early PCI. We pooled existing data and performed
a meta-analysis.
Methods: Medline, PubMed and abstracts from major cardiology conferences were
searched. Randomized control trials (RCTs) comparing the composite of death and/or
myocardial infarctions (MI) and/or repeat revascularization within 6 months of early
or delayed PCI for high risk patients with NSTE-ACS were included. High risk was
deﬁned as TIMI score >5 or GRACE score >140. The effects of both methods were
analyzed by calculating pooled estimates for death, MI and repeat revascularization.
Analyses were performed for the outcome by using odds ratio (OR) by random effects
model. Heterogeneity among studies was assessed by calculating I00 measure of
inconsistency.
Results: Three studies (ACUITY, ELISA-3 and TIMACS) with a total of 3090
patients met our inclusion criteria. The incidence of the composite of death and/or MI
and/or repeat revascularization was not different between early PCI [207/1422
(14.5%)] as compared to delayed PCI [310/1668(18.6%)], (OR 0.72, 95% CI 0.51-
1.01, P¼0.06).Conclusions: Coronary artery revascularization within 24 hours of presentation does
not reduce composite of death and/or MI and/or repeat revascularization at 6 months
in high risk NSTE-ACS as compared to intervention after 24 hours. More studies are
needed on this subgroup of NSTE-ACS patients.
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Background: Delayed endothelial coverage of stent struts has been linked to late stent
thrombosis, especially after drug-eluting stent implantation. The high-resolution
capability of intravascular optical coherence tomography (OCT) enables visualization
of strut coverage and has been used to quantify coverage at various time points post
implantation. This has the potential application of predicting timing and safety of dual
anti-platelet therapy discontinuation. We aim to summarize all known quantitative
strut level analysis data of clinically implanted coronary stents in human subjects to
date as evaluated by OCT.
Methods: A review of publications and online databases up to February 2013
retrieved 59 eligible articles and abstracts, 1843 initially identiﬁed studies. Data
extracted for bare metal, (BMS), Sirolimus (SES), Paclitaxel (PES), Zotarolimus
(ZES-E & ZES-R) and Everolimus eluting stent (EES) strut coverage and malap-
position was compared between stents at various time intervals post implantation.
Results: 13 abstracts and 46 papers were included in the analysis with studies per-
formed from 1 week to 5 years post implantation. 2,278 patients were studied,
comprising 2,716 stents, 2,044 lesions and strut level data on 532,533 struts, where
data was recorded.
Conclusions: Bare metal stents achieved a threshold of < 2.0% uncovered struts
within 1 month of implantation, SES within 48 months, PES within 60 months,
Endeavor ZES within 2.5 months and EES within 20 months. Resolute ZES have
a 7.4% uncovered strut rate at 13 months post-implantation and lack data beyond this.
OCT enables direct visualization and quantiﬁcation of coronary stent delayed endo-
thelial coverage at a strut level, providing insight into drug eluting stent-speciﬁc
effects on the timing of neo-intimal healing. This may have a role in predicting drug-
eluting-stent speciﬁc safety of dual-antiplatelet therapy cessation.acts/POSTER/Meta-Analyses and Reviews B255
